Tissue peptide-specific antigen TPS Product Launch Event with complete success

Tissue peptide-specific antigen TPS Product Launch Event with complete success.

On May 27, ZECEN successfully held the TPS new product launch conference at CACLP in Nanchang.

Participants included experts from Sweden's IDL biotech, experts from China's in vitro diagnostic industry, professors and partners from many hospitals, etc.

ZECEN Biotech Tissue Peptide Specific Antigen Detection Kit (Chemiluminescence Immunoassay), 2022 Obtained the registration certificate in 20222402231 with the registration number of SCFDA.

A large amount of clinical comparison data shows that the reagent kit and the "Tissue peptide specific antigen" produced by IDL Biotech AB company, which has been approved for marketing in China.

The test kit (enzyme-linked immunosorbent assay, National Machinery Injection No. 20182401810) has high consistency,R=0.9998.

Zecen Biotech TPS is derived from the gold standard and can therefore serve as an early stage for the progression of epithelial tumors and metastatic cancers signal, used for the full process management of tumor patients.

In addition, IDL biotech AB has established a strategic cooperative relationship with Zecen Biotech, in the fully automatic

continue Jointly develop tumor markers on the chemiluminescence platform, and then UBC, TKI and other projects will contribute to the Chinese and even international IVD industry.

For more exciting, please pay attention to the following video.